Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement

N/ANot Yet RecruitingNCT06131489

Beijing Friendship Hospital20 enrolled

Overview

EBV-HLH is a rare disease with high mortality, especially for those with intestinal involvement. In order to reduce disease burden and improve survival of these patients, we conduct a prospective observational study to explore the efficacy and safety of segmental resection combined with the DEP regimen.

Epstein-Barr virus associated hemophagocytic lymphohistiocytosis is a rare disease with high mortality, especially for those with intestinal involvement. Some of them still died despite early control of the disease due to severe complications, such as gastrointestinal bleeding. In order to reduce disease burden and improve survival of these patients, we conduct a prospective observational study to explore the efficacy and safety of segmental resection combined with the DEP regimen.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hemophagocytic Lymphohistiocytosis Epstein-Barr Virus Bowel Resection

Interventions

Segmental bowel resection combined with the DEP regimenOTHER

Segmental bowel resection combined with liposomal doxorubicin, etoposide, and methylprednisolone administered in 2 week cycles for 2 cycles

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Met HLH-2004 diagnostic criteria; * EBV-DNA in the peripheral blood \> 1000 copies/ml or EBV-encoded small RNA (EBER) detected in tissues; * Imaging revealed severe intestinal lesions and biopsy confirmed EBV-encoded small RNA (EBER) in the tissues; * Age \>18 years old, gender is not limited; * Estimated survival time \> 1 month; * Informed consent obtained. Exclusion Criteria: * Active infections (viral, bacterial, fungal or parasitic); * Diagosed with malignant tumos within 5 years； * Uncontrolled symptoms or other diseases including, but not limited to, unstable angina pectoris, arrhythmia, respiratory failure, severe hepatic or renal insufficiency, severe coagulation dysfunction, mental illness, or other conditions deemed by the attending physician to be contraindications to surgery; * Heart function above grade II (NYHA); * Severe myocardial injury：TNT、TNI、CK-MB \> 3 ULN; * Accumulated dose of doxorubicin above 400mg/m2 、epirubicin above 750mg/m2、pirarubicin above 800mg/m2 or the patients treated with anthracycline induced cardiovascular disease; * Pregnancy or lactating Women; * Allergic to pegylated liposomal doxorubicin and etoposide; * HIV antibody positivity; * Acute or chronic active hepatitis B (HBsAg positivity, HBV DNA negative acceptable), acute or chronic active hepatitis C (HCV antibody negatively acceptable; HCV antibody positivity, HCV RNA negative acceptable); * Participate in other clinical research at the same time; * The researchers considered that patients are not suitable for the study.

Locations (1)

Zhao Wang

Beijing, Beijing Municipality, China

Outcomes

Primary Outcomes

ORR

The percentage of cases that achieved complete response (CR) and partial response (PR) after treatment.

Time frame: 4 Week

Adverse events

Incidence of adverse reactions

Time frame: 1 month

Secondary Outcomes

Overall survival rate

Time frame: 1 years

Central Contacts

Zhao Wang, MD

CONTACT

63138303 wangzhao@ccmu.edu.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.